RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

Cancer Letters

Volumn 299, Issue 1, 2010, Pages 22-28

  Lee, Kyung Hun ^a   Hur, Hyung Seok ^a   Im, Seock Ah ^a   Lee, Juhee ^a   Kim, Hwang Phill ^a   Yoon, Young Kwang ^a   Han, Sae Won ^a   Song, Sang Hyun ^a   Oh, Do Youn ^a   Kim, Tae You ^a,b   Bang, Yung Jue ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Gastric cancer; MTOR; RAD001; Thymidylate synthase

Indexed keywords

CYTOTOXIC AGENT; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; THYMIDYLATE SYNTHASE; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH CANCER; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; G1 PHASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; EVEROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 77957891539     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.020     Document Type: Article

References (37)

1. Ajani J.A., Fodor M.B., Tjulandin S.A., Moiseyenko V.M., Chao Y., Cabral Filho S., Majlis A., Assadourian S., Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. 2005, 23:5660-5667.
2. Chon H.J., Rha S.Y., Im C.K., Kim C., Hong M.H., Kim H.R., An J.R., Noh S.H., Chung H.C., Jeung H.C. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase ii trials. Cancer Res. Treat. 2009, 41:196-204.
3. Kang H.J., Chang H.M., Kim T.W., Ryu M.H., Sohn H.J., Yook J.H., Oh S.T., Kim B.S., Lee J.S., Kang Y.K. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br. J. Cancer 2005, 92:246-251.
4. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
5. Vignot S., Faivre S., Aguirre D., Raymond E. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16:525-537.
6. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100:657-666.
7. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism in growth and metabolism. Cell 2006, 124:471-484.
8. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 2003, 4:343-348.
9. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
10. Huang S., Bjornsti M.A., Houghton P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2003, 2:222-232.
11. Oki E., Baba H., Tokunaga E., Nakamura T., Ueda N., Futatsugi M., Mashino K., Yamamoto M., Ikebe M., Kakeji Y., Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int. J. Cancer 2005, 117:376-380.
12. Lang S.A., Gaumann A., Koehl G.E., Seidel U., Bataille F., Klein D., Ellis L.M., Bolder U., Hofstaedter F., Schlitt H.J., Geissler E.K., Stoeltzing O. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 2007, 120:1803-1810.
13. Saga Y., Suzuki M., Mizukami H., Urabe M., Fukushima M., Ozawa K., Sato I. Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation. Oncology 2002, 63:185-191.
14. Pandyra A.A., Berg R., Vincent M., Koropatnick J. Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. J. Pharmacol. Exp. Ther. 2007, 322:123-132.
15. Xi Y., Nakajima G., Schmitz J.C., Chu E., Ju J. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genom. 2006, 7:68.
16. Chu E., Callender M.A., Farrell M.P., Schmitz J.C. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother. Pharmacol. 2003, 1(Suppl. 52):S80-89.
17. Copur S., Aiba K., Drake J.C., Allegra C.J., Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol. 1995, 49:1419-1426.
18. Kawate H., Landis D.M., Loeb L.A. Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J. Biol. Chem. 2002, 277:36304-36311.
19. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55:1407-1412.
20. Leichman L., Leichman C.G. Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology. Eur. J. Surg. 2001, (Suppl.):43-48.
21. Mizutani Y., Wada H., Yoshida O., Fukushima M., Nonomura M., Nakao M., Miki T. Significance of thymidylate synthase activity in renal cell carcinoma. Clin. Cancer Res. 2003, 9:1453-1460.
22. Nomura T., Nakagawa M., Fujita Y., Hanada T., Mimata H., Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int. J. Urol. 2002, 9:368-376.
23. Park J.G., Yang H.K., Kim W.H., Chung J.K., Kang M.S., Lee J.H., Oh J.H., Park H.S., Yeo K.S., Kang S.H., Song S.Y., Kang Y.K., Bang Y.J., Kim Y.H., Kim J.P. Establishment and characterization of human gastric carcinoma cell lines. Int. J. Cancer 1997, 70:443-449.
24. Park J.G., Kramer B.S., Steinberg S.M., Carmichael J., Collins J.M., Minna J.D., Gazdar A.F. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res. 1987, 47:5875-5879.
25. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
26. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994, 86:1517-1524.
27. Kim H.P., Han S.W., Kim S.H., Im S.A., Oh D.Y., Bang Y.J., Kim T.Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008, 7:607-615.
28. Hidalgo M., Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19:6680-6686.
29. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98:10314-10319.
30. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl. Cancer Inst. 2001, 93:1517-1519.
31. Noh W.C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., Mills G.B., Hung M.C., Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004, 10:1013-1023.
32. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
33. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
34. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., Natt F., Hall J., Lane H.A., Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
35. Wendel H.G., Malina A., Zhao Z., Zender L., Kogan S.C., Cordon-Cardo C., Pelletier J., Lowe S.W. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006, 66:7639-7646.
36. Cejka D., Preusser M., Fuereder T., Sieghart W., Werzowa J., Strommer S., Wacheck V. MTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res. 2008, 28:3801-3808.
37. Cejka D., Preusser M., Woehrer A., Sieghart W., Strommer S., Werzowa J., Fuereder T., Wacheck V. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol. Ther. 2008, 7:1377-1385.